CEO Ronan O’Caoimh Increases Shareholding in Trinity Biotech
November 29 2018 - 8:58AM
Trinity Biotech plc (Nasdaq: TRIB), today announced that Ronan
O’Caoimh, CEO of Trinity Biotech, has increased his shareholding in
Trinity Biotech by the acquisition of 425,000 ADRs. As a result of
this transaction, Mr. O’Caoimh’s shareholding in Trinity Biotech
has increased from 1,339,374 ADRs to 1,764,374 ADRs which
represents 8.4% of the company’s share capital excluding the impact
of share options. The increase in shareholding was due to shares
purchased in the open market. This was in addition to the purchase
of 430,000 ADRs by Ronan O’Caoimh which was announced in June 2018.
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
Contact: Trinity Biotech plc Kevin Tansley
(353)-1-2769800 E-mail:
kevin.tansley@trinitybiotech.com
Lytham Partners LLCJoe Diaz, Joe Dorame &
Robert Blum602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Sep 2023 to Sep 2024